Literature DB >> 11107092

Adventitial versus intimal liposome-mediated ex vivo transfection of canine saphenous vein grafts with endothelial nitric oxide synthase gene.

M Kalra1, C J Jost, S R Severson, V M Miller.   

Abstract

PURPOSE: Experiments were designed (1) to evaluate liposome-mediated endothelial constitutive nitric oxide synthase (ecNOS) transfection in vein grafts and (2) to compare intimal and adventitial routes of transfection.
METHODS: Male mongrel dogs (N = 36) underwent bilateral femoral artery bypass grafting with the lateral saphenous vein. In each animal one vein was transfected with plasmid (pVR1012) containing the ecNOS gene, and another vein was transfected with plasmid alone (control). Gene transfer was performed from either the intimal surface (Group I, n = 18) or the adventitial surface (Group II, n = 18). In each group there were three transfection subgroups (n = 6 each): (a ) 10 microg/mL naked plasmid DNA, (b ) 10 microg/mL plasmid DNA + liposome (LipofectAMINE PLUS), and (c ) 100 microg/mL plasmid DNA + LipofectAMINE PLUS. Grafts were harvested on the third postoperative day, and the transfection was assessed with molecular techniques and enzyme assay for activity of NOS by conversion of tritiated l-arginine to tritiated l-citrulline. Proliferating cells were quantified with a digital analysis of histologic sections after nuclear antigen Ki-67 (MIB1) immunohistochemistry.
RESULTS: Transgene was identified with polymerase chain reaction in all ecNOS-transfected grafts, regardless of transfection modality. However, significant transcription of the ecNOS transgene was observed only in Group IIc (mean ecNOS messenger RNA, 8.7+/-1.7 vs. 3.1+/-0.7 x 10(-2) attomole/microL, in transfected compared with control grafts, respectively, P =.01). NOS activity increased approximately twofold in this group (11.58+/-2.1 and 6.3+/-1.0 pmol tritiated l-citrulline per milligram protein per hour in transfected and control grafts, respectively, P = .05). Numbers of proliferating cells did not differ among ecNOS-transfected and control grafts in any transfection group.
CONCLUSION: These results suggest that ecNOS transfection of vein grafts is feasible through intimal and adventitial routes with naked DNA or a liposomal vector. However, efficient transcription of the transgene is evident at postoperative day 3 only after adventitial transfection of 100 microg/mL of the gene.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11107092     DOI: 10.1067/mva.2000.109211

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  6 in total

1.  Evidence supporting changes in Nogo-B levels as a marker of neointimal expansion but not adaptive arterial remodeling.

Authors:  Jacek J Paszkowiak; Stephen P Maloney; Fabio A Kudo; Akihito Muto; Desarom Teso; Reuben C Rutland; Tormod S Westvik; Jose M Pimiento; George Tellides; William C Sessa; Alan Dardik
Journal:  Vascul Pharmacol       Date:  2006-11-18       Impact factor: 5.773

2.  Experimental study of tissue-type plasminogen activator gene to prevent vein grafts stenosis.

Authors:  Xionggang Jiang; Xiaobin Liu; Kailun Zhang; Jiahong Xia; Daokang Xiang; Long Wu; Cheng Zhou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

Review 3.  Cardiovascular gene delivery: The good road is awaiting.

Authors:  L P Brewster; E M Brey; H P Greisler
Journal:  Adv Drug Deliv Rev       Date:  2006-07-07       Impact factor: 15.470

4.  Non-viral eNOS gene delivery and transfection with stents for the treatment of restenosis.

Authors:  Luis A Brito; Saradha Chandrasekhar; Steven R Little; Mansoor M Amiji
Journal:  Biomed Eng Online       Date:  2010-09-27       Impact factor: 2.819

Review 5.  Nanoparticulate carriers for the treatment of coronary restenosis.

Authors:  Luis Brito; Mansoor Amiji
Journal:  Int J Nanomedicine       Date:  2007

Review 6.  Nanoparticle drug- and gene-eluting stents for the prevention and treatment of coronary restenosis.

Authors:  Rui-Xing Yin; De-Zhai Yang; Jin-Zhen Wu
Journal:  Theranostics       Date:  2014-01-08       Impact factor: 11.556

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.